The Biologics News and Reports Portal

Show Cart

All Products

Results 1 - 20 of 194

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

120.00 €

Feb 2023 CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

1,800.00 €

Nov 2022 RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape an

2,350.00 €

Jul 2022 Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

1,800.00 €

Jul 2022 GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

600.00 €

Jun 2022 ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

1,050.00 €

May 2022 Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

400.00 €

May 2022 Claudin 6: A target opportunity to develop effector-enhanced drug modalities

500.00 €

Mar 2022 Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2,450.00 €

Oct 2021 Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

2,250.00 €

Jun 2021 Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2,150.00 €

May 2020 Report Package: “Drug the Undruggable” Technologies

4,125.00 €

8,250.00 €

(Discount: 50.00%)

May 2020 Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2,050.00 €

Apr 2020 STING Agonists & Antagonists – Target Pipeline List 04/2020

150.00 €

Mar 2020 Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

90.00 €

Feb 2020 TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020

100.00 €

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

600.00 €

Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

All Products

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Feb 2023 CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Nov 2022 RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape an

Jul 2022 Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Jul 2022 GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Jun 2022 ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

May 2022 Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

May 2022 Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Mar 2022 Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Oct 2021 Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Jun 2021 Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

May 2020 Report Package: “Drug the Undruggable” Technologies

May 2020 Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Apr 2020 STING Agonists & Antagonists – Target Pipeline List 04/2020

Mar 2020 Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Feb 2020 TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Oct 2019 Competitor Analysis: KRAS Inhibitors

Sep 2019 Competitor Analysis: TGF-beta/Receptor Inhibitors

Sep 2019 Competitor Analysis: RORgamma Antagonists and Agonists

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing